Arcadia Biosciences Chief Growth Officer Chris Cuvelier to Depart Nov 30, 2021

Arcadia Biosciences, Inc.

Chris Cuvelier's employment as Chief Growth Officer will end effective November 30, 2021.
The decision was reached on November 15, 2021, as reported by Arcadia Biosciences.
The company filed an 8-K with the SEC on November 19, 2021, disclosing the officer departure.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Chris Cuvelier

Chief Growth Officer

RKDA · Arcadia Biosciences, Inc.

Effective: 2021-11-30
Filed: November 19, 2021, 6:59 PM ET

On November 15, 2021, Arcadia Biosciences, Inc. (the “Company”) and Chris Cuvelier determined that Mr. Cuvelier's employment as the Company’s Chief Growth Officer will end effective as of November 30, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Chris Cuvelier departed as Chief Growth Officer at Arcadia Biosciences, Inc..

Action: will end
Role: Chief Growth Officer

Exact text from the filing

On November 15, 2021, Arcadia Biosciences, Inc. (the “Company”) and Chris Cuvelier determined that Mr. Cuvelier's employment as the Company’s Chief Growth Officer will end effective as of November 30, 2021.

View on SEC.gov

Arcadia Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-21-004812

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.